HYALURONIDASE D016
Breaking boundaries in tissue science. D016 is our innovative enzyme that, for the first time, combines the unique mechanisms of action of PH20 and HYAL4. This enables it to break down both classical hyaluronic acid and particularly resilient chondroitin sulphate–containing tissue structures.
Available for licensing and supply: We offer D016 for research, medical, and industrial applications worldwide.
CREATING HEALTH
Medical and cosmetic progress emerges from the synergy of research and practice.
Pharmact stands for innovations that push boundaries: with the genetically optimised enzyme, we offer a powerful solution for the cosmetics industry as well as for pioneering biopharmaceutical developments of new medicines.
Our contribution to better health – and to compelling opportunities in a growing market.
OUR COMPANY
About Us Learn more about the philosophy, team, values, and history of our corporate group.
Projects & Innovations Discover our enzyme D016 and our active substance approval project BELACT – prime examples of our scientific and technological progress.
Investor Relations Access all key information for investors, from current figures and reports to news and upcoming events.
NEWS PRODUCTS
Screening for metabolic diseases on early stages
The effective therapy of diabetes mellitus and arteriosclerosis as well as their sequelae is one of the greatest medical challenges of our time. More…
NEW PROJECTS
New substance in registration process
Arteriosclerosis is a silent disease that partially leads to calcifying hardening of the arterial system. Pharmact has developed a specific drug that is available from the beginning of Q2. 2020. The substance has now been entered the drug approval process.